Lenalidomide Alkaloid-Int (Lenalidomide)

Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its activity so that specific transcription factors such as Ikaros and Aiolos are marked for degradation. This results in reduced production of pro‑inflammatory cytokines, inhibition of new blood‑vessel formation, enhanced natural killer cell function, and direct anti‑tumor activity against malignant plasma cells.

The prescribed dose of Lenalidomide Alkaloid-Int is determined by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosing regimens may differ between multiple myeloma and myelodysplastic syndrome protocols, and adjustments are made according to laboratory monitoring and clinical response.

Lenalidomide is classified as Pregnancy Category X because it is known to cause fetal harm and is contraindicated in pregnancy. Women of childbearing potential must use effective contraception before, during, and after treatment. The safety of lenalidomide during breastfeeding has not been established, and nursing is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing a formal quotation, availability details, shipping terms, and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, offering a distinct mechanism from proteasome inhibitors and monoclonal antibodies. Compared with older agents like thalidomide, lenalidomide generally has a more favorable side‑effect profile, especially regarding neuropathy, while providing comparable or superior efficacy when combined with dexamethasone or other backbone therapies.

Lenalidomide Alkaloid-Int should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity, and ensure the container is tightly closed when not in use.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. Patients should follow the specific schedule provided, which may involve daily dosing for a set number of days followed by a rest period, depending on the treatment protocol.

The most serious risks include severe neutropenia or thrombocytopenia that can lead to infection or bleeding, venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, hepatotoxicity, and the potential for secondary primary malignancies. Patients should be monitored closely for these events, and any signs of serious adverse reactions require immediate medical attention.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to the drug or its components, and patients who cannot adhere to the required risk‑management program. Caution is also advised for those with severe renal impairment, uncontrolled infections, or a history of thromboembolic events unless appropriate prophylaxis is in place.